Taysha Gene Therapies Inc (TSHA) returns
Taysha Gene Therapies returns over 5 years
$1,000 invested in Taysha Gene Therapies five years ago was worth $264.07 at the close on October 30, 2026, with dividends reinvested: an average return of -23.4% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -15.2% | — | $848.05 | -0.9% |
| 3 months | -29.7% | — | $702.98 | +2.1% |
| Year to date | -24.9% | — | $750.91 | +11.7% |
| 1 year | -15.9% | — | $841.14 | +12.4% |
| 3 years | +82.7% | +22.3% | $1,827 | +88.5% |
| 5 years | -73.6% | -23.4% | $264.07 | +76.0% |
Taysha Gene Therapies return by calendar year
| Year | TSHA | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -24.9% | +11.7% | -36.6% |
| 2025 | +217.9% | +17.7% | +200.2% |
| 2024 | -2.3% | +24.9% | -27.1% |
| 2023 | -21.7% | +26.2% | -47.9% |
| 2022 | -80.6% | -18.2% | -62.4% |
| 2021 | -56.1% | +28.7% | -84.8% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: TSHA financials
No forecast, no recommendation. This page describes Taysha Gene Therapies Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.